Denali Therapeutics (DNLI) EBT Margin (2018 - 2023)
Denali Therapeutics (DNLI) reported EBT Margin of 7841.59% for Q3 2023, up 4829917.0% year-over-year from N/an in Q3 2022, and down 12676.92% quarter-over-quarter from 62.35% in Q2 2023.
Denali Therapeutics (DNLI) EBT Margin (2018 - 2023) Analysis & Trends
Denali Therapeutics (DNLI) has 6 years of EBT Margin data on file, last reported at 7841.59% in Q3 2023.
- EBT Margin for Q3 2023 came in at 7841.59%, up 4829917.0% year-over-year; the trailing twelve-month figure through Jun 2024 was 33119.49% (down 3308167.0% YoY), and the FY2023 annual result was 43.93%, up 954907.0% from the prior year.
- EBT Margin slipped to 7841.59% in Q3 2023 per DNLI's latest filing, from 62.35% in the prior quarter.
- Over five years, EBT Margin peaked at 77.56% in Q4 2020 and troughed at 7004100.0% in Q1 2021.
- A 5-year average of 445036.66% and a median of 1003.57% in 2020 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2021 and 2022: EBT Margin tumbled 689468077 bps in 2021, then surged 700394220 bps in 2022.
- A 5-year view of EBT Margin shows it stood at 1236.26% in 2019, then jumped by 106 bps to 77.56% in 2020, then sank by 881 bps to 606.01% in 2021, then tumbled by 63 bps to 986.84% in 2022, then sank by 695 bps to 7841.59% in 2023.
- Business Quant data shows DNLI's EBT Margin at 7841.59% in Q3 2023, 62.35% in Q2 2023, and 312.4% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -7,841.59% |
| Jun 30, 2023 | 62.35% |
| Mar 31, 2023 | -312.40% |
| Dec 31, 2022 | -986.84% |
| Sep 30, 2022 | -56,140.76% |
| Jun 30, 2022 | -111.98% |
| Mar 31, 2022 | -157.80% |
| Dec 31, 2021 | -606.01% |
| Sep 30, 2021 | -1,600.53% |
| Jun 30, 2021 | -404.61% |
| Mar 31, 2021 | -7,004,100.00% |
| Dec 31, 2020 | 77.56% |
| Sep 30, 2020 | -1,163,440.00% |
| Jun 30, 2020 | -1,003.57% |
| Mar 31, 2020 | -109,419.23% |
| Dec 31, 2019 | -1,236.26% |
| Sep 30, 2019 | -48,305.21% |
| Jun 30, 2019 | -59,242.42% |
| Mar 31, 2019 | -927.28% |
| Dec 31, 2018 | 61.72% |